FDA approves new treatment for rare blood disorder essential thrombocythemia

The FDA has approved ropeginterferon alfa-2b-njft (BESREMi) for adults with essential thrombocythemia (ET), a rare blood disorder. This marks the first new therapeutic option for ET in almost 30 years, offering a significant advancement for patients. The approval is based on Phase 3 clinical trial data demonstrating superior efficacy and a favorable safety profile compared to existing treatments.